Results 31 to 40 of about 451,745 (342)

Anti-HIV-1 activity of benzothiadiazine dioxide [PDF]

, 2013
Antiviral assays carried out on the potent benzothiadiazine dioxide (BTD) human cytomegalovirus (HCMV) inhibitors have led us to find marginal but selective anti-HIV-1 activity.
Balzarini, Jan, Castro, Ana, De Clercq, Erik, Gil, Carmen, Martínez, Ana, Pannecouque, C., Pérez, Concepción, Witvrouw, M.   +7 more
core   +2 more sources

Drogas anti-VIH: passado, presente e perspectivas futuras Drugs anti-HIV: past, present and future perspectives

Química Nova, 2003
Currently available anti-HIV drugs can be classified into three categories: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Marcus Vinícius Nora de Souza, Mauro Vieira de Almeida   +1 more
doaj   +1 more source

Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.

Journal of Medicinal Chemistry, 2019
To address drug resistance to HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs), a series of novel diarylpyrimidine (DAPY) derivatives targeting "tolerant region I" and "tolerant region II" of the NNRTIs binding pocket (NNIBP) were designed ...
Dongwei Kang, Heng Zhang, Zhao Wang, Tong Zhao, Tiziana Ginex, F. Luque, Yang Yang, Gaochan Wu, Da Feng, Fenju Wei, Jian Zhang, E. De Clercq, C. Pannecouque, Chin-Ho Chen, K. Lee, N. A. Murugan, T. Steitz, P. Zhan, Xinyong Liu   +18 more
semanticscholar   +1 more source

HIV - recentes avanços na pesquisa de fármacos HIV - highlights in drug research

Química Nova, 2008
The development of new antiretroviral drugs is a dynamic process that is continuously fueled by identification of new molecular targets and new compounds for know targets.
Wilson Cunico, Claudia R. B. Gomes, Walcimar T. Vellasco Junior   +2 more
doaj   +1 more source

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]

, 2016
To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel, Borch, Alexandra, De Scheerder, Marie-Angélique, De Spiegelaere, Ward, Koenig, Renate, Malatinková, Eva, Melkova, Zora, Vandekerckhove, Linos   +7 more
core   +1 more source

A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs

International Journal of Electrochemistry, 2011
Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal, Bengi Uslu, Sibel A. Özkan   +2 more
doaj   +1 more source

High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs

Nature Communications, 2021
Initiation of HIV-1 reverse transcription occurs at the host tRNALys 3, which forms a complex with the 5’ end of the HIV-1 viral RNA and reverse transcriptase (RT).
Betty Ha, Kevin P. Larsen, Jingji Zhang, Ziao Fu, Elizabeth Montabana, Lynnette N. Jackson, Dong-Hua Chen, Elisabetta Viani Puglisi   +7 more
doaj   +1 more source

The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase [PDF]

Trends in Pharmaceutical Sciences
HIV-1 reverse transcriptase (RT) is a crucial enzyme in HIV replication and AIDS progression. It consists of p66 and p51 subunits and converts viral RNA into double-stranded DNA for integration into the host cell's genome.
Roohallah Yousefi
doaj   +1 more source

Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014 [PDF]

, 2016
Resistance to antiretroviral agents is a significant concern in the clinical management of HIV-infected individuals, particularly in areas of the world where treatment options are limited.
Aghasadeghi, M.R., Baesi, K., Davarpanah, M.A., McFarland, W., Moradi, A., Naziri, H., Tabarraei, A.   +6 more
core   +1 more source

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source